|
Market Closed -
NYSE
16:00:00 2026-08-17 EDT
|
5-day change | 1st Jan Change | ||
| 1.060 USD | -0.93% |
|
-6.19% | -36.53% |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 268.1 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -33.76% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 268.1 | 268.1 | 268.1 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -33.76% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -15.8x | -10.2x | 133x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.2x | -0.2x | -1x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 17.6x | 15.9x | 4.49x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 17.6x | 15.9x | 4.49x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -7.97x | -9.12x | -8.74x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -8.45x | -9.76x | 41.1x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -22.3x | -30.1x | 73.4x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -4.48% | -3.32% | 1.36% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.0671 | -0.1043 | 0.008 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 15.19 | 16.83 | 59.72 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -33.64 | -29.41 | -30.66 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -31.71 | -27.47 | 6.528 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -22.64 | -34.44 | 6.022 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.450 | 1.170 | 1.090 | 0.502 | 1.670 | 1.060 | 1.060 | 1.060 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 252,907 | - | - |
| Announcement Date | 3/10/22 | 3/9/23 | 3/7/24 | 3/10/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.79x | - | - | - | 268M | |
| 33.26x | 5.94x | 17.67x | 0.96% | 48.84B | |
| -22x | 301.52x | -22.38x | -.--% | 45.44B | |
| 47.49x | 5.5x | 30.07x | -.--% | 41.22B | |
| 31.07x | 3.07x | 13.27x | -.--% | 39.71B | |
| 30.58x | 8.82x | 22.17x | 0.38% | 32.6B | |
| 33.96x | 5.56x | 25.28x | -.--% | 16.67B | |
| 23.34x | 2.04x | 8.84x | 1.15% | 14.08B | |
| 76.69x | 4.04x | 15.66x | -.--% | 13.68B | |
| Average | 26.51x | 42.06x | 13.82x | 0.31% | 28.06B | |
| Weighted average by Cap. | 26.74x | 58.69x | 12.27x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
